The research team set out to answer a deceptively simple question: if Iran were to launch a fully organized, population-based breast cancer screening program tomorrow, what would it need to fix first? To do this rigorously, the investigators designed a three-stage convergent mixed-methods study. In the first stage, they conducted a systematic literature review, screening 953 records and retaining seven high-quality studies from which they extracted the building blocks of an assessment checklist. This checklist covered the domains that international guidelines consider essential for organized screening: target population definition, invitation and recall systems, diagnostic follow-up, workforce and equipment, information systems, financing, and performance monitoring.

Because a checklist built from a handful of studies could miss locally relevant criteria, the researchers then convened a two-round Delphi panel of six experts to refine and validate the instrument. The Delphi technique, a structured consensus method in which experts score and comment on items across successive rounds until agreement stabilizes, allowed the team to merge international evidence with the practical judgment of Iranian policy makers and clinicians. Only after the checklist had been finalized and validated did the team apply it, drawing on the data gathered in the literature review together with six semi-structured interviews with policy makers, oncologists, and frontline healthcare providers who run screening services on the ground.

The picture that emerged is one of a system with real assets but weak connective tissue. Iran does have a national guideline for breast cancer screening, and it has a broad network of health centers and screening facilities distributed across the country. Trained personnel exist, and public awareness campaigns about breast cancer have been running for years. Yet implementation of screening remains inconsistent from province to province, with significant disparities in access, resource allocation, and program reach. In practice, most screening is opportunistic: women are examined when they happen to visit a health facility for another reason, rather than being systematically identified, invited, and followed up by the health system.

This distinction between opportunistic and organized screening is more than bureaucratic hair-splitting. In organized programs, the health system maintains a registry of the eligible population, issues personal invitations at prescribed intervals, tracks every woman who fails to attend, and monitors outcomes such as cancer detection rates and interval cancers. Opportunistic screening, by contrast, systematically misses women who are less likely to seek care, and it produces uneven quality because there is no mechanism to verify that examinations and mammography readings meet standards. The Iranian study found that key performance indicators, including early detection rates and follow-up completion rates, are not systematically monitored anywhere in the program, which makes it nearly impossible to know whether screening is actually saving lives or merely generating activity.

Technical and administrative weaknesses compound the problem. The researchers documented manual data management across much of the screening pathway, meaning that records of examinations, referrals, and diagnostic outcomes are often kept on paper or in disconnected local systems rather than in an integrated electronic registry. Without such a registry, no invitation-based program can function, because the system cannot know who is due for screening, who has been screened, and who needs recall for suspicious findings. The study also identified insufficient dedicated funding for screening as a persistent constraint, with resources for promotion, equipment maintenance, and follow-up competing against other priorities in health budgets that are not ring-fenced for cancer control.

The interviews with frontline providers and specialists added texture to these structural findings. Providers described the practical consequences of limited proactive outreach: women in remote and underserved provinces may live far from mammography facilities, may not receive any reminder that screening is due, and may encounter the health system only when symptoms appear, often at later and harder-to-treat stages. Policy makers acknowledged that although Iran’s primary health care network, one of the most extensive in the region, reaches deep into rural areas, that network has not been fully harnessed for systematic cancer screening in the way it has for maternal and child health or for the management of other non-communicable diseases through initiatives such as IraPEN, the Iranian package of essential non-communicable disease services.

What makes the study notable for health policy observers is that it does not simply catalog failures. The authors emphasize that Iran’s established infrastructure, trained personnel, and ongoing awareness campaigns constitute a strong foundation on which an organized program could be built relatively quickly. The country’s primary health care system already assigns populations to specific health houses and health centers, which is precisely the catchment structure that invitation-based screening requires. The missing elements are the information systems to register and track eligible women, sustainable and dedicated financing, continued workforce development in mammography technique and reading, and a monitoring framework with defined indicators that are routinely reported and acted upon.

As a feasible pathway forward, the study proposes piloting an invitation-based screening model in selected provinces or defined catchment areas before attempting national scale-up. This incremental approach mirrors the trajectory followed by many countries that successfully transitioned from opportunistic to organized mammography screening: demonstrate the model in a manageable setting, measure coverage and quality indicators, fix the operational problems that only appear in practice, and then expand. The authors argue that such pilots would generate the local evidence on costs, acceptance, and logistics needed to convince decision makers to invest in the integrated electronic systems and monitoring frameworks that a national program demands.

The stakes are considerable. Because breast cancer is the top cause of cancer death among Iranian women, and because survival depends strongly on the stage at which the disease is detected, the difference between a functioning organized screening program and an opportunistic one is measured in lives. The study, conducted as part of the first author’s PhD thesis in health policy and approved by the ethics committee of Tehran University of Medical Sciences, received no specific external funding and involved no competing interests. Its message to Iran’s health authorities is direct: the foundations are in place, the checklist for success has now been written and validated, and the next step is a deliberate, monitored shift from waiting for women to arrive to actively inviting them in.

Subject of Research: Situation analysis of the breast cancer screening system in Iran using a mixed-methods design

Article Title: Situation analysis of breast cancer screening in Iran: a mixed-methods study

Article References: Dorri Kafrani, S., Akbari Sari, A., Yunesian, M., Moadabshoar, L., & Daroudi, R. (2026). Situation analysis of breast cancer screening in Iran: a mixed-methods study. International Journal for Equity in Health. https://doi.org/10.1186/s12939-026-02991-z

Image Credits: AI Generated

DOI: 10.1186/s12939-026-02991-z

Keywords: breast cancer screening, Iran, organized screening, opportunistic screening, health system assessment, Delphi method, mammography, health equity, non-communicable diseases, screening policy, primary health care, mixed methods

The authors build their case from a series of revealing examples drawn from British screening history. The UK National Screening Committee recommended against population-based prostate cancer screening, concluding that while screening prevented prostate cancer deaths, it also caused harm through overdiagnosis and overtreatment, leaving some men with urinary incontinence or erectile dysfunction. In reaching that conclusion, the committee made a value judgement about how to weigh extended life against morbidity — and, the authors note, it assumed without evidence that individual men would share its values. Meanwhile, when Wales extended the cervical screening interval for women aged 25 to 49 from three years to five in 2022, a scientifically defensible decision triggered a public outcry and a petition signed by more than a million people, prompting England to delay the same change until July 2025.

Bowel screening illustrates how resources quietly shape supposedly clinical thresholds. The faecal immunochemical test, or FIT, applies a binary cut-off to the amount of blood in a stool sample, and that cut-off ranges from 8.5 to 150 micrograms of haemoglobin per gram of faeces across programmes, largely to manage colonoscopy capacity. Historically, Wales used a threshold of 150, England 120 and Scotland 80 micrograms per gram — meaning a result deemed normal in England could have triggered a colonoscopy just across the Scottish border. The stakes of delay are also stark: randomised trials showed guaiac-based faecal occult blood testing reduced colorectal cancer mortality as early as 1996, yet England’s screening programme only completed roll-out in 2010. Screening now prevents roughly 2,000 colorectal cancer deaths annually in England; had it rolled out in 2000, the authors estimate some 20,000 premature deaths could have been averted.

To make sense of such cases, Sasieni and John adapt five principles for decision-making under uncertainty — proportionality, justice, autonomy, feasibility and adaptability — into a framework specifically for cancer screening. Their central claim is that policymakers suffer from an asymmetry of fear: they worry intensely about false-positive decisions, such as introducing a screening programme that turns out to do more harm than good, while largely ignoring false-negative decisions, in which beneficial programmes are delayed or withheld. Because committees periodically revisit recommendations, a cautious ‘not yet’ feels reversible and safe. But delay has consequences that can be quantified even without certainty. If prostate screening in men aged 50 to 65 reduces prostate cancer mortality by 25 percent over 15 years, a two-decade implementation delay could translate into around 20,000 avoidable deaths in the UK. Conversely, had multimodal ovarian cancer screening been introduced for women aged 50 to 74 before the definitive UKCTOCS trial results, roughly 7,000 women each year might have undergone unnecessary surgery. Both sides of the ledger can be estimated, the authors argue, and should be before decisions are made.

The principle of justice exposes another hidden cost of slowness: inequality. Wealthy and well-educated people frequently obtain screening privately long before public programmes roll out. In the United States, colonoscopy use is 50 percent higher in the wealthiest socioeconomic quintile than in the poorest. In England, prostate-specific antigen testing is 25 percent lower in the most deprived quintile — and metastatic prostate cancer rates there are 11 percent higher, while overall prostate cancer incidence is 19 percent lower, plausibly reflecting inequitable access to asymptomatic PSA testing. Justice also complicates the details: some researchers argue FIT referral thresholds should differ for women and men, but the right answer depends on which measure of equity one chooses to prioritise, a value judgement that should be made transparently. Even overdiagnosis falls unevenly — introducing prostate screening for men in their seventies would generate more overdiagnosis among the most deprived, whose shorter life expectancy means more of them die of other causes before screening could ever help.

Autonomy poses a deeper philosophical problem. Public health typically overrides individual preferences for the collective good, while clinical medicine demands informed consent. Screening sits awkwardly between: society seeks consent before screening anyone, yet takes a paternalistic stance on what screening is offered at all, rarely considering the ethics of denying screening to those who want it. The authors suggest a more democratic division of labour, inspired by the Dutch model: expert committees could summarise evidence and uncertainties without issuing recommendations, forcing elected politicians to make the value-laden choices explicitly. Where experts disagree, politicians should decide. They even sketch a personalised option for prostate screening — inviting men aged 50 to 69 for triennial PSA testing without encouraging participation, letting personal risk tolerance guide the decision, much as oncology patients weigh their own treatment choices.

Feasibility, the authors stress, already governs screening policy whether it is admitted or not. FIT thresholds and age ranges are set by colonoscopy capacity; MRI-based prostate screening would demand vast new infrastructure of scanners and staff; and in low- and middle-income countries, cervical screening is constrained by the lack of facilities to triage screen-positive women and treat precancerous lesions. Public opinion constrains policy too — hence the continued offering of cervical screening at age 25 to women vaccinated against HPV as adolescents, despite their extremely low cervical cancer risk and the likelihood that screening does them more harm than good. The authors argue the public is mature enough to understand these trade-offs, provided they are communicated honestly.

Adaptability may be the most urgent principle in an era of artificial intelligence and liquid biopsies. Traditional screening trials are ruinously expensive — the National Lung Cancer Screening Trial cost 256 million dollars in 2002, roughly 400 million today — and a binary framework of full national implementation or complete rejection leaves no pathway for pragmatic pilots that generate evidence while delivering benefit. Multicancer detection tests sharpen the dilemma: by the time one test’s clinical utility is fully evaluated, the technology will be outdated, and trial designs that test each cancer type separately would require randomising millions of people. The authors call for publicly funded pilots designed to fill evidence gaps, with implementation beginning in health-deprived regions to address injustice rather than widen it. They are candid about the risks of permissiveness — a pilot ovarian screening programme before 2021 would have harmed some healthy women with false positives — but insist those harms and benefits could and should have been estimated in advance, and that any new decision-making system should itself be monitored and reformed if it fails.

The paper’s conclusion is disarmingly simple: presenting screening policy as a straightforward application of evidence-based medicine obscures profound ethical and political choices, and delaying a decision is itself a decision against change — one measured in preventable deaths, avoidable morbidity and widening inequality. As AI begins to exceed human radiologists and pathologists, quantifying future disease risk and optimising screening intervals, governance structures built around static population interventions and decade-long trials will be unable to evaluate products superseded every five years. Who decides, on what basis, and how quickly — the authors argue — are questions that can no longer be left unasked.

Subject of Research: Ethical and policy frameworks for cancer screening decision-making under uncertainty

Article Title: The clinical consequences of excessive caution: rethinking how cancer screening policy is made

Article References: Sasieni, P., & John, S. (2026). The clinical consequences of excessive caution: rethinking how cancer screening policy is made. eClinicalMedicine, Article 104188. https://doi.org/10.1016/j.eclinm.2026.104188

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104188

Keywords: cancer screening, screening policy, decision-making under uncertainty, health inequalities, prostate cancer screening, bowel cancer screening, multicancer detection tests, artificial intelligence, overdiagnosis, public trust, clinical, consequences